Author Archives: Marisa Wexler, MS

Low-dose IL-2 Reduces Disease Activity in SLE, Trial Results Suggest

Adding low-dose interleukin-2 (IL-2) to standard therapy increases responses and complete remission of lupus nephritis in patients with systemic lupus erythematosus (SLE), results of a randomized clinical trial suggest. Patients on IL-2 had higher proportions of regulatory T cells, a subset of immune T cells associated with…